Aclaris Therapeutics Inc

Research Aclaris Therapeutics Inc (ACRS) on Bullrun: market cap USD 913.75M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 913.75M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 7.83M-USD 64.92M-USD 47.22M73.3%-0.53USD 19.96Mn/aUSD 103.08M
FY2024USD 18.72M-USD 132.07M-USD 20.20M85.1%-1.71USD 24.57Mn/aUSD 155.55M
FY2023USD 31.25M-USD 88.48M-USD 79.63M89.0%-1.27USD 39.88MUSD 426.00KUSD 157.18M
FY2022USD 29.75M-USD 86.91M-USD 68.17M86.5%-1.33USD 45.28MUSD 684.00KUSD 197.62M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 913.75Mn/an/an/a
20252025-12-31USD 362.70Mn/an/an/a
20242024-12-31USD 267.47Mn/an/an/a
20232023-12-29USD 74.38Mn/an/an/a
20222022-12-30USD 1.05Bn/an/an/a
20212021-12-31USD 890.26Mn/an/an/a

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Aclaris Therapeutics Inc's market cap?

Aclaris Therapeutics Inc's market capitalization is USD 913.75M.

What does Aclaris Therapeutics Inc do?

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.